Market

The target market segments include in vitro diagnostics for HIV and cancers, and nanoparticle therapeutics for cancers, asthma and chronic respiratory diseases. The Global market size for these target segments was $100 billion in 2003 and is expected to double in size within the next 10 years. This presents a very sizable opportunity for TGN products. In addition, TGN is developing and selling custom nanoparticle reagents for various other applications.





© Copyright 2003, TransGenex Nanobiotech (see Website Agreement)